Wells Fargo
TCRX icon

Wells Fargo’s TScan Therapeutics TCRX Stock Holding History

Wells Fargo’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-323
Closed -$468 – 7385
2025
Q2 		$468 Sell
323
-19,892
-98% -$28.7K ﹤0.01% 6378
2025
Q1 		$27.9K Buy
20,215
+675
+3% +$1.46K ﹤0.01% 5598
2024
Q4 		$59.4K Buy
19,540
+5,694
+41% +$25.8K ﹤0.01% 5420
2024
Q3 		$69K Sell
13,846
-40
-0.3% -$241 ﹤0.01% 5215
2024
Q2 		$81.2K Buy
13,886
+13,580
+4,438% +$107K ﹤0.01% 5064
2024
Q1 		$2.43K Buy
306
+5
+2% +$31 ﹤0.01% 5995
2023
Q4 		$1.75K Buy
301
+15
+5% +$69 ﹤0.01% 6124
2023
Q3 		$732 Buy
286
+206
+258% +$481 ﹤0.01% 6272
2023
Q2 		$200 Buy
80
+5
+7% +$13 ﹤0.01% 6706
2023
Q1 		$158 Buy
75
+2
+3% +$5 ﹤0.01% 6835
2022
Q4 		$113 Buy
73
+1
+1% +$2 ﹤0.01% 6766
2022
Q3 		$0 Buy
72
+26
+57% +$85 ﹤0.01% 7348
2022
Q2 		$0 Buy
46
+5
+12% +$14 ﹤0.01% 7473
2022
Q1 		$0 Hold
41
– – ﹤0.01% 7795
2021
Q4 		$0 Hold
41
– – ﹤0.01% 7794
2021
Q3 		$0 Buy
+41
New +$380 ﹤0.01% 7507

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Wells Fargo's TCRX Position: Q3 2025 in Review

Wells Fargo sold out of TScan Therapeutics (TCRX) in Q3 2025, closing a stake of 323 shares — an estimated $468 sold.

Wells Fargo first reported a position in TCRX in Q3 2021 and held it in 16 quarters. The position peaked at $81.2K in Q2 2024. 73 funds tracked by Wall St. Rank hold TCRX as of Q3 2025.

  • Wells Fargo reported no remaining TScan Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wells Fargo sold 323 TScan Therapeutics shares in Q3 2025, an estimated $468.
  • Wells Fargo first reported a position in TScan Therapeutics in Q3 2021 and held it in 16 quarters.
  • Wells Fargo's TScan Therapeutics position peaked at $81.2K in Q2 2024.
  • 73 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2025.

Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.